Vagus nerve stimulation (VNS) therapy update

James Wheless, Andrew J. Gienapp, Phillippe Ryvlin

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Epilepsy affects millions of people worldwide. Approximately one-third have pharmacoresistant epilepsy, and of these, the majority are not candidates for epilepsy surgery. Vagus nerve stimulation (VNS) therapy has been an option to treat pharmacoresistant seizures for 30 years. In this update, we will review the clinical data that support the device's efficacy in children, adolescents, and adults. We will also review its side-effect profile, quality of life and cost benefits, and the impact the device has on sudden unexpected death in epilepsy (SUDEP). We will then discuss candidate selection and provide guidance on dosing and future models. Vagus nerve stimulation therapy is an effective treatment for many seizure types and epilepsy syndromes with a predictable and benign side-effect profile that supports its role as the most commonly prescribed device to treat pharmacoresistant epilepsy. “This article is part of the Supplement issue Neurostimulation for Epilepsy.”

Original languageEnglish (US)
Pages (from-to)2-10
Number of pages9
JournalEpilepsy and Behavior
Volume88
DOIs
StatePublished - Nov 1 2018

Fingerprint

Vagus Nerve Stimulation
Epilepsy
Equipment and Supplies
Therapeutics
Seizures
Sudden Death
Cost-Benefit Analysis
Quality of Life

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Vagus nerve stimulation (VNS) therapy update. / Wheless, James; Gienapp, Andrew J.; Ryvlin, Phillippe.

In: Epilepsy and Behavior, Vol. 88, 01.11.2018, p. 2-10.

Research output: Contribution to journalReview article

Wheless, James ; Gienapp, Andrew J. ; Ryvlin, Phillippe. / Vagus nerve stimulation (VNS) therapy update. In: Epilepsy and Behavior. 2018 ; Vol. 88. pp. 2-10.
@article{3e40283f293d46169ba4c44c5ce5c3a2,
title = "Vagus nerve stimulation (VNS) therapy update",
abstract = "Epilepsy affects millions of people worldwide. Approximately one-third have pharmacoresistant epilepsy, and of these, the majority are not candidates for epilepsy surgery. Vagus nerve stimulation (VNS) therapy has been an option to treat pharmacoresistant seizures for 30 years. In this update, we will review the clinical data that support the device's efficacy in children, adolescents, and adults. We will also review its side-effect profile, quality of life and cost benefits, and the impact the device has on sudden unexpected death in epilepsy (SUDEP). We will then discuss candidate selection and provide guidance on dosing and future models. Vagus nerve stimulation therapy is an effective treatment for many seizure types and epilepsy syndromes with a predictable and benign side-effect profile that supports its role as the most commonly prescribed device to treat pharmacoresistant epilepsy. “This article is part of the Supplement issue Neurostimulation for Epilepsy.”",
author = "James Wheless and Gienapp, {Andrew J.} and Phillippe Ryvlin",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.yebeh.2018.06.032",
language = "English (US)",
volume = "88",
pages = "2--10",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Vagus nerve stimulation (VNS) therapy update

AU - Wheless, James

AU - Gienapp, Andrew J.

AU - Ryvlin, Phillippe

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Epilepsy affects millions of people worldwide. Approximately one-third have pharmacoresistant epilepsy, and of these, the majority are not candidates for epilepsy surgery. Vagus nerve stimulation (VNS) therapy has been an option to treat pharmacoresistant seizures for 30 years. In this update, we will review the clinical data that support the device's efficacy in children, adolescents, and adults. We will also review its side-effect profile, quality of life and cost benefits, and the impact the device has on sudden unexpected death in epilepsy (SUDEP). We will then discuss candidate selection and provide guidance on dosing and future models. Vagus nerve stimulation therapy is an effective treatment for many seizure types and epilepsy syndromes with a predictable and benign side-effect profile that supports its role as the most commonly prescribed device to treat pharmacoresistant epilepsy. “This article is part of the Supplement issue Neurostimulation for Epilepsy.”

AB - Epilepsy affects millions of people worldwide. Approximately one-third have pharmacoresistant epilepsy, and of these, the majority are not candidates for epilepsy surgery. Vagus nerve stimulation (VNS) therapy has been an option to treat pharmacoresistant seizures for 30 years. In this update, we will review the clinical data that support the device's efficacy in children, adolescents, and adults. We will also review its side-effect profile, quality of life and cost benefits, and the impact the device has on sudden unexpected death in epilepsy (SUDEP). We will then discuss candidate selection and provide guidance on dosing and future models. Vagus nerve stimulation therapy is an effective treatment for many seizure types and epilepsy syndromes with a predictable and benign side-effect profile that supports its role as the most commonly prescribed device to treat pharmacoresistant epilepsy. “This article is part of the Supplement issue Neurostimulation for Epilepsy.”

UR - http://www.scopus.com/inward/record.url?scp=85049726757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049726757&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2018.06.032

DO - 10.1016/j.yebeh.2018.06.032

M3 - Review article

VL - 88

SP - 2

EP - 10

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

ER -